KEYTRUDA aNSCLC data are practice changing
Posted on

During ASCO, Breaking Data asked 30 oncologists to select which solid tumor abstracts had the most potential to impact their practice. The chart depicts the number of oncologists (out of 30) that believe the data has the potential to impact their practice. KEYTRUDA aNSCLC data are practice changing. The adjuvant melanoma update for OPDIVO, mCRPC data for KEYTRUDA and aNSCLC data for TECENTRIQ also have the potential to change practice.

ABSTRACTS:

PROSTATE | KEYNOTE-199: Pembrolizumab  for docetaxel-ref metastatic castration-resistant prostate cancer

LUNG | KEYNOTE-042: Pembro vs platinum-based chemo as 1L therapy for advanced NSCLC with a PD-L1 tumor proportion score ≥1%: Open-label, phase 3

LUNG | KEYNOTE-407: Phase 3: carbo plus paclitaxel or nab-paclitaxel ± pembrolizumab for patients with metastatic squamous NSCLC

MELANOMA | CheckMate 238: Adjuvant therapy with nivolumab vs ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase III trial

LUNG | IMpower131: Primary PFS and safety analysis of a randomized phase 3 study of atezolizumab + carbo + pac or nab-pac vs carbo + nab-pac in 1L advanced squamous NSCLC

BREAST | SANDPIPER: Phase 3 study of taselisib + fulvestrant vs fulvestrant in patients with ER-positive, PIK3CA-mutant, locally advanced or metastatic breast cancer

RET-altered Cancers | phase 1: LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers

BREAST | MONALEESA-3: Ribociclib + fulvestrant in postmenopausal women with HR+, HER2– advanced breast cancer


Source: Breaking Data: 2018 American Society of Oncology (ASCO) Impact Analysis Report: Solid Tumors

advanced non-small cell lung cancer (aNSCLC)

Quote Icon
Practice changing because the results were positive in PD-L1-negative patients; therefore pembro can be added to chemo in the 1L setting in metastatic squamous NSCLC; PD-L1 status doesn’t matter. -Academic Oncologist